Dr. Stefanie Flückiger-Mangual

Co-Founder & CEO, TOLREMO therapeutics AG

Dr. Stefanie Flückiger-Mangual is co-founder and CEO of TOLREMO therapeutics AG, which was founded in 2017. TOLREMO is a spin-off from ETH Zurich and is developing a new type of booster drug with the aim of increasing the efficacy of anti-cancer drugs. The first molecule developed by TOLREMO is currently being tested in an international clinical trial in cancer patients.

Stefanie Flückiger holds a Bachelor's degree in Biomedicine from the University of Fribourg and a Master's degree in Biochemistry from ETH Zurich. She completed her PhD at ETH, specialising in cancer drug resistance mechanisms. After completing her PhD, she worked as a postdoc at ETH, where she laid the scientific foundations for the subsequent founding of TOLREMO.